Gilead’s Profit, Hepatitis C Drugs Sales Miss EstimatesBy
Sovaldi, Harvoni sales disappoint after competitors appear
Company is `aggressively' seeking investment opportunities
Gilead Sciences Inc.’s profit missed analysts’ estimates in the first quarter as sales of its blockbuster hepatitis C treatments were lower than expected.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.